Clinical Trial, Phase II, randomized, double-blind, placebo-controlled, 1-way over with 2 treatment periods of 40 weeks duration.Applicants: Research Group CTS546. IBIMA. Regional University Hospital. Málaga.Subjects: Patients above 55 years with depressive disorders.

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

• Diagnosis of mild depression smaller or larger by Mini International Neuropsychiatric Interview (MINI).
• Having more than 55 years old
• Have signed the informed consent document before you start participating in the trial.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 25
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 25

Exclusion Criteria

• Individuals with other psychiatric diagnosis as the first diagnosis.
• To have suffered serious medical problems in the last 12 months.
• Are taking more than 100mg of vitamin E or C a day in the last 4 months.
• Having physical, mental or sensory problems that prevent the assessment of effectiveness.
• Hypersensitivity to any component of the preparation.
• Previous pathology of kidney stones

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

Phase 2, randomized, double-blind, two-way crossover, placebo-controlled clinical trial of the efficacy and safety of Mucuna pruriens seed extract in men with mild and mild to moderate erectile dysfunctio

Phase 2

Faculty of Medicine, Chiang Mai University

Updated 8/19/2024

A Phase II, double-blind, randomized, cross-over, international,multicentre study to evaluate the analgesic efficacy of 3 weeks oraladministration of AZD4282 300 mg b.i.d. compared with placebo inposttraumatic neuralgia

Phase 1

AstraZeneca AB

Updated 10/3/2016

A Phase II, double-blind, randomized, cross-over, international,multicentre study to evaluate the analgesic efficacy of 3 weeks oraladministration of AZD4282 300 mg b.i.d. compared with placebo inpostherpetic neuralgia

Phase 1

AstraZeneca AB

Updated 10/3/2016

A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensitivity in GERD patients with a partial response to PPI treatment - na

AstraZeneca AB

Updated 3/19/2012

A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensitivity in GERD patients with a partial response to PPI treatment - na

AstraZeneca AB

Updated 3/19/2012

A Phase 2, randomized, double-blind, cross-over study of S-600918 in subjects with refractory/unexplained chronic cough

CompletedPhase 2

Shionogi & Co., Ltd.

Updated 10/17/2023

A Phase I randomised, double-blind, 2-way cross-over study to compare the peripheral vasodilatation following treatment with DRL 21994 or NIASPAN® and to determine the pharmacokinetics of DRL 21994 in healthy, adult male subjects under fed conditions.

Withdrawn

Dr. Reddy's Laboratories Ltd.

Updated 5/6/2024

A phase I/II study to evaluate the Salmonella Typhi Vi polysaccharide vaccine – vax-TyVi – in children and teenagers.

Phase 1

Finlay Institute

Updated 8/19/2024

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, delivered with the Respimat® Inhaler, after 3 Weeks of Olodaterol Once Daily 5 µg [2 actuations of 2.5 µg], Twice Daily 2.5 µg [2 actuations of 1.25 µg] and Placebo or after 3 Weeks of Once Daily 10 µg [2 actuations of 5 µg], Twice Daily 5 µg [2 actuations of 2.5 µg] and Placebo Administration in Patients with Moderate to Severe Persistent Asthma

Phase 1

Boehringer Ingelheim RCV GmbH & Co KG

Updated 6/30/2019

Phase II, Randomised, Double-Blind, Cross-over Study to Compare the24-hour FEV1-time Profile of Orally Inhaled Olodaterol, delivered withthe Respimat® Inhaler, after 3 Weeks of Olodaterol Once Daily 5 µg [2actuations of 2.5 µg], Twice Daily 2.5 µg [2 actuations of 1.25 µg] andPlacebo or after 3 Weeks of Once Daily 10 µg [2 actuations of 5 µg],Twice Daily 5 µg [2 actuations of 2.5 µg] and Placebo Administrationin Patients with Moderate to Severe Persistent Asthma

Boehringer Ingelheim RCV GmbH & Co KG

Updated 5/1/2012

Clinical Trial, Phase II, randomized, double-blind, placebo-controlled, 1-way over with 2 treatment periods of 40 weeks duration.Applicants: Research Group CTS546. IBIMA. Regional University Hospital. Málaga.Subjects: Patients above 55 years with depressive disorders.

Recruitment & Eligibility

Study & Design

Related Trials

Phase 2, randomized, double-blind, two-way crossover, placebo-controlled clinical trial of the efficacy and safety of Mucuna pruriens seed extract in men with mild and mild to moderate erectile dysfunctio

A Phase II, double-blind, randomized, cross-over, international,multicentre study to evaluate the analgesic efficacy of 3 weeks oraladministration of AZD4282 300 mg b.i.d. compared with placebo inposttraumatic neuralgia

A Phase II, double-blind, randomized, cross-over, international,multicentre study to evaluate the analgesic efficacy of 3 weeks oraladministration of AZD4282 300 mg b.i.d. compared with placebo inpostherpetic neuralgia

A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensitivity in GERD patients with a partial response to PPI treatment - na

A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensitivity in GERD patients with a partial response to PPI treatment - na

A Phase 2, randomized, double-blind, cross-over study of S-600918 in subjects with refractory/unexplained chronic cough

A Phase I randomised, double-blind, 2-way cross-over study to compare the peripheral vasodilatation following treatment with DRL 21994 or NIASPAN® and to determine the pharmacokinetics of DRL 21994 in healthy, adult male subjects under fed conditions.

A phase I/II study to evaluate the Salmonella Typhi Vi polysaccharide vaccine – vax-TyVi – in children and teenagers.

Clinical Trial Alerts

Clinical Trial Alerts